1 Spatiotemporal evolution of the ccRCC microenvironment links intra-tumoral

2 heterogeneity to immune escape

- 3 Mahdi Golkaram,¹ Fengshen Kuo,² Sounak Gupta,³ Maria I. Carlo,⁴ Michael L. Salmans,¹ Raakhee Vijayaraghavan,¹
- 4 Cerise Tang,⁵ Vlad Makarov,^{2,5} Phillip Rappold,⁵ Kyle A. Blum,^{2,5,6} Chen Zhao,¹ Rami Mehio,¹ Shile Zhang,¹ Jim
- 5 Godsey,¹ Traci Pawlowski,¹ Renzo G. DiNatale,^{2,5,6} Luc GT Morris,⁷ Jeremy Durack,⁸ Paul Russo,⁶ Ritesh R. Kotecha,⁴
- 6 Jonathan Coleman.⁶ Ying-Bei Chen,³ Victor E Reuter,³ Robert J Motzer,⁴ Martin H. Voss,⁴ Li Liu,^{1,15,*} Ed Reznik,^{6,9,10,15,*}
- 7 Timothy A. Chan, 2,11,12,13,14,15,* and A. Ari Hakimi^{2,6,15,16,*}
- 8 ¹Illumina, Inc., 5200 Illumina Way, San Diego, CA 92122, USA
- 9 ²Immunogenomics and Precision Oncology Platform, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 10 ³Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 11 ⁴Department of Medicine, Genitourinary Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, NY 10065, USA
- 12 ⁵Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 13 ⁶Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 14 ⁷Department of Surgery, Head & Neck Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 15 ⁸Interventional Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 16 ⁹Computational Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- 17 ¹⁰Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA
- 18 ¹¹Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
- 19 ¹²Center for Immunotherapy and Precision Immuno-Oncology, Cleveland Clinic, Cleveland, OH 44195, USA
- 20 ¹³Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
- 21 ¹⁴National Center for Regenerative Medicine, Cleveland Clinic, Cleveland, OH 44195, USA
- 22 ¹⁵Senior author
- 23 ¹⁶Lead contact
- 24 *Correspondence: reznike@mskcc.org, (E.R.), lliu3@illumina.com (L.L), chant2@ccf.org (T.A.C.), hakimia@mskcc.org (A.A.H).
- 25
- 26

27 Abstract

28 Background

Intratumoral heterogeneity (ITH) is a hallmark of clear cell renal cell carcinoma (ccRCC) that reflects the trajectory of evolution and influences clinical prognosis. Here we seek to elucidate how ITH and tumor evolution during immune checkpoint inhibitor (ICI) treatment can lead to therapy resistance.

33

34 Methods

Here, we spatiotemporally profiled the genomic and immunophenotypic characteristics of 29
 ccRCC patients, including pre- and post-therapy samples from 17 ICI treated patients.

37 Deep multi-regional whole exome and transcriptome sequencing were performed on 29 patients 38 at different time points before and after ICI therapy. T cell repertoire was also monitored from 39 tissue and peripheral blood collected from a subset of patients to study T cell clonal expansion 40 during ICI therapy.

41

42 Results

Angiogenesis, lymphocytic infiltration, and myeloid infiltration varied significantly across regions of the same patient, potentially confounding their utility as biomarkers of ICI response. Elevated ITH associated with a constellation of both genomic features (HLA LOH, CDKN2A/B loss) and microenvironmental features, including elevated myeloid expression, reduced peripheral T cell receptor (TCR) diversity, and putative neoantigen depletion. Hypothesizing that ITH may itself play a role in shaping ICI response, we derived a transcriptomic signature associated with

- 49 neoantigen depletion that strongly associated with response to ICI and targeted therapy treatment
- 50 in several independent clinical trial cohorts.

51

52 **Conclusions**

53 These results argue that genetic and immune heterogeneity jointly co-evolve and influence 54 response to ICI in ccRCC.

55

56 **Trial registration**

57 We completed a single-arm pilot study at Memorial Sloan Kettering Cancer Center (MSKCC; 58 ClinicalTrials.gov identifier NCT02595918) to examine the safety and feasibility of neoadjuvant 59 nivolumab in patients with localized RCC.

60

61 Background

62 Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of kidney 63 cancer and demonstrates a high response rate to immune checkpoint inhibitors such as 64 nivolumab, pembrolizumab and ipilimumab [1-3]. However, only a subset of ccRCC patients 65 respond to ICI, and biomarkers for ICI response in other disease settings such as tumor mutation 66 burden, neoantigen load and mismatch repair deficiency do not associate with ICI response in 67 ccRCC [4-7]. Recently, several studies have identified transcriptomic microenvironmental 68 features including angiogenic gene expression, T-cell infiltration, and myeloid activation that 69 correlate with response or resistance to ICI and combination therapies in ccRCC [7-13]. This 70 suggests that the ccRCC microenvironment, in addition to genomic factors, influences ICI 71 response.

72 In parallel, recent work has demonstrated the prevalence of ITH in untreated ccRCC [14]. This study has largely focused on heterogeneity in the presence of key driver mutations and copy 73 74 number alterations and have demonstrated that ccRCC tumors follow one of a small number of 75 evolutionary trajectories, each of which are associated with distinct patterns of genomic ITH and 76 clinical prognosis. However, the potential for non-genomic heterogeneity in the tumor 77 microenvironment, including but not limited to variability in the amount and identity of immune 78 cells in spatially distinct regions of the same tumor is overlooked. Recently, we and others 79 described substantial heterogeneity in the tumor-microenvironment (TME) in several small 80 cohorts of ccRCC tumors both in the treatment-naïve and treatment-exposed settings, raising the 81 possibility that heterogeneity in the TME may itself shape the evolution of the tumor and its 82 likelihood to respond to therapy [15, 16].

83

84 In this study, we hypothesized ccRCC tumors with elevated ITH constitute a genomically 85 and immunologically distinct class of tumors, with distinguishing clonal/subclonal genomic 86 alterations, immunologic profiles, and therapeutic response trajectories. To test this hypothesis, 87 we utilize whole exome sequencing (WES), whole transcriptome sequencing (WTS), TCRseq, 88 and histopathologic multi-regional data across a cohort of untreated and ICI exposed patients 89 from a phase 2 clinical trial to reveal the molecular determinants of therapy response in ccRCC 90 (Fig. 1 and Table S1). Our integrated analysis demonstrated that ITH is highly correlated among 91 genomic, transcriptomic, and TME characteristics. ITH-high tumors are enriched for features 92 including SETD2 and PBRM1 mutations, HLA loss of heterozygosity (HLA LOH), and CDKN2A/B 93 loss. Immunologically, ITH-high tumors display a depletion of putative neoantigens, elevated 94 myeloid activation, and reduced T cell diversity, that are in aggregate associated with escape 95 from the anti-tumor immune response. Premised on these observations, we developed a

- 96 transcriptional signature for immune escape which correlates with distinct histopathologic patterns
- 97 and is associated with ICI resistance across several diverse clinical trial cohorts.
- 98

99 Materials and Methods

100 Sample acquisition

101 After acquiring informed consent and institutional review board approval from Memorial 102 Sloan Kettering Cancer Center (MSK), partial or radical nephrectomies were performed at MSK 103 (New York) and stored at the MSK Translational Kidney Research Program (TKRCP). Samples 104 were flash frozen and stored at -80 degrees Celsius prior to molecular characterization. Clinical 105 metadata was recorded for all tumor samples. All patients represent clear cell histology and were 106 treated via ICI alone or in combination with tyrosine kinase inhibitor (TKI). All treatments were 107 administered prior to surgery in a neo-adjuvant setting and biopsies were collected. Detailed 108 clinical data and treatment regimen for each patient is included in Table S2.

109

110 Untreated cohort

Using and institutional database we identified six patients with advanced or metastatic
ccRCC that underwent nephrectomy with multiregional data available MR01,02,03,05,06, SC03.
Clinical and pathologic data is available in Table S2.

114

115 Neoadjuvant multiregional cohort

This open-label, single-arm, pilot study was done at Memorial Sloan Kettering Cancer
 Center and funded through the National Institute of Health's Cancer Therapy Evaluation Program
 (CTEP). Patients received nivolumab (dose initially 3 mg/kg, then protocol amended to 240 mg

119 flat dose) every 2 weeks for 4 treatments. Surgery was planned 7-14 days after the last dose. 120 Prior to starting therapy, all patients had a kidney biopsy to confirm ccRCC, and tumor staging 121 with renal protocol MRI and CT of the chest. After 4 doses and prior to surgery, patients also had 122 a renal protocol MRI. Changes in primary tumor size were assessed according to Response 123 Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Resection of the primary tumor and 124 lymph nodes was done according to standard institutional procedures. From May 27, 2016, to 125 September 9, 2019, 21 patients were screened and 18 were enrolled into the study of which 17 126 had available genomic data. Baseline patient characteristics are in Supplementary Table S2. All 127 patients had localized disease at time of enrollment and biopsy-proven clear cell RCC. 128 Perioperative and pathological details are included in Supplementary Table S2. Median time to 129 nephrectomy after the last dose of nivolumab was 10.5 days (range, 9-13 days).

130

131 Metastatic multiregional Cohort

Using an institutional database, we identified 6 additional patients who had received ICI
prior to nephrectomy (Supplementary Table S2). All patients had metastatic disease at time of
ICI; two received anti-VEGF therapies before ICI.

135

136 Multi-regional sampling

For the prospective neoadjuvant trial and the "MR" samples single region biopsies were obtained preoperatively. Following nephrectomy, tumor were bivalved and 5 regions were chosen: One region from the tumor center and 4 from each quadrant (upper medial, upper later, lower medial, lower lateral). Grossly necrotic or hemorrhagic regions were avoided. For the remaining samples (those treated with definitive immunotherapy "SC") regions were taken from distinct regions of tumors separated by 1-2 cm avoiding grossly necrotic or hemorrhagic regions).

143

144 Whole exome sequencing

145 Libraries for whole exome sequencing were generated with TruSight Oncology DNA 146 Library Prep Kit with 40ng input DNA per sample. TruSight Oncology index PCR products were 147 directly used for enrichment and target exome enrichment was performed using the IDT xGen 148 Universal Blockers and IDT xGen Exome Research panel. A single-plex hybridization was done 149 overnight at 65°C. Accuclear dsDNA Ultra High Sensitivity assay (Biotium) was used for library 150 guantification of the post-enriched libraries. Post enrichment libraries were normalized using 151 bead-based normalization and pooled. Samples were sequenced with 101 bp paired-end reads 152 on Illumina NovaSeq[™] 6000 S4 flow cell using the XP workflow for individual lane loading (12-153 plex per lane). On average. each sample vielded 500 million reads and 154 MEDIAN TARGET COVERAGE depth of 360X.

155

156 Whole transcriptome sequencing

Libraries for whole transcriptome RNA-seq were generated with Illumina TruSeq Stranded Total RNA. 100 ng RNA was used as input for Ribo-Zero rRNA Removal Kit, with Illumina TruSeq RNA UD Indexes (96 indexes) for sample indexing. Qubit dsDNA High Sensitivity assay (Thermo Fisher Scientific) was used for library quantification. Sequencing was done on Illumina NovaSeq[™] 6000 S2 (36-plex) or S4 (72-plex) flow cell with 76 bp paired-end sequencing to produce ~200 million paired reads per library.

163

164 **T-cell repertoire sequencing**

Libraries for T-cell repertoire sequencing were generated with AmpliSeq for Illumina Library PLUS paired with AmpliSeq cDNA Synthesis for Illumina with 100 ng RNA input per cDNA synthesis reaction. The TCR beta-SR Panel was used for generating amplicons, and AmpliSeq CD Indexes Set A for Illumina were used for sample barcodes. Qubit dsDNA High Sensitivity assay (Thermo Fisher Scientific) was used for library quantification. Sequencing was done on the NextSeq 550 (41-plex) with 151 bp paired-end sequencing to produce ~5 million paired reads per library.

172

173 WTS pipeline

174 WTS raw read sequences were aligned against human genome assembly hg19 by STAR 175 2-pass alignment [17]. QC metrics, for example general sequencing statistics, gene feature and 176 body coverage, were then calculated based on the alignment result through RSeQC. WTS gene 177 level count values were computed by using the R package GenomicAlignments [18] over aligned 178 reads with UCSC KnownGene [19] in hg19 as the base gene model. The union counting mode 179 was used and only mapped paired reads after alignment quality filtering were considered. Finally, 180 gene level FPKM (Fragments Per Kilobase Million) and raw read count values were computed by 181 the R package DESeg2 [20].

182

183 ESTIMATE

184 The ESTIMATEScore, which is the estimate of the presence of stromal and immune cells 185 in tumor tissue, is calculated through the ESTIMATE R package [21] based on a given gene 186 expression profile in FPKM.

188 Immune deconvolution analysis

189 Two distinct popular computational methods, ssGSEA [22] and CIBERSORT [23], were 190 chosen for immune deconvolution analysis. Signature gene lists of immune cell types for ssGSEA 191 were obtained from Bindea et al. [24] and Senbabaoglu et al. [3]. ssGSEA takes the sample FPKM 192 WTS expression values as the input and computes an enrichment score for the given gene list of 193 immune cell type relative to all other genes in the transcriptome. On the other hand, CIBERSORT 194 also takes FPKM WTS expression values as the input but uses a signature gene expression 195 matrix of interest immune cell types instead to compute the infiltration level of each immune cell 196 type. The LM22 immune cell signature which was validated and published along with 197 CIBERSORT is used. We also used FRICTION [25] to deconvolute WTS into absolute CD8 and 198 CD4 T cells as well as CD19 B cells.

199

200 **HERV** quantification

We used WTS to quantify HERVs as described before [25]. Briefly, all WTS reads were aligned (using STAR aligner with optimized multi mapping options) to a custom genome built were human reference (hg19) and HERV specific reference are combined. Then reads aligned to non-HERV genes are removed and the rest are annotated. 3 samples contained super high median HERVs (Grubbs test P<0.05) and removed for better visualization.

206

207 WES analysis pipeline

208 Raw sequencing data were aligned to the hg19 genome build using the Burrows-Wheeler 209 Aligner (BWA) version 0.7.17 [26]. Further indel realignment, base-quality score recalibration and 210 duplicate-read removal were performed using the Genome Analysis Toolkit (GATK) version 3.8 211 [27] following raw reads alignments guidelines [28]. VarScan 2 [29], Strelka v2.9.10 [30], Platypus

212	0.8.1 [31], Mutect2 – part of GATK 4.1.4.1 [28], Somatic Sniper version 1.0.5.0 (SNVs only), and			
213	[32] were used for small variant calling and combination of 2 out 5 callers are reported as per			
214	Cancer Genome Atlas Research Network recommendations [33]. Variants were filtered using the			
215	following criteria:			
216	1. Tcov > 10 & Taf >=0.04 & Ncov > 7 & Naf <= 0.01 & Tac > 4 are set to Pass			
217	2. Common SNPs are eliminated by comparison to snp142.vcf			
218	3. Rare variants found in dbSNP are kept if Naf = 0			
219	4. Variants with Tcov < 20 or Tac < 4 are marked as low_confidence			
220	5. Only variants called by more than 1 caller are reported.			
221	6. Common variables gnomAD v 2.1.1 are excluded.			
222	Variants were annotated using Ensembl Variant Effect Predictor (VEP) [34]. Additional			
223	optimization and filtering are applied for INDELS. INDELS in blacklisted regions			
224	(https://www.encodeproject.org/annotations/ENCSR636HFF/) and low mappability regions (such			
225	as repeat maskers) are excluded as per [35]. Combination of filtered SNV and INDELS are used			
226	by maftools R package is used to generate oncoplots and summary plots, as per author's			
227	recommendations			
228	https://www.bioconductor.org/packages/release/bioc/vignettes/maftools/inst/doc/maftools.html			
220	All nonovnonymous point mutations identified as shows were translated into strings of 17			

All nonsynonymous point mutations identified as above were translated into strings of 17 amino acids with the mutant amino acid situated centrally using a bioinformatics tool called NAseek. A sliding window method is used to identify the 8-11 amino acid substrings within the mutant 17-mer that had a predicted MHC Class I binding affinity of \leq 2 %Rank to one (or more) of the patient-specific HLA alleles. Binding affinity for the mutant and corresponding wild type

nonamer is analyzed using NetMHCpan4.0 software. Only neoantigens with a TPM>1 areconsidered to be expressed.

Allele-specific copy number analysis is done by the FACETS v.6.1 [36]. Allele specific HLA
 loss is determined using LOHHLA as described before [37].

238

239 RNA and TCR ITH scores

240 Gene- and patient-wise intra-patient heterogeneity scores were calculated using multi-241 region data. Data was first median-centered to remove any gene-level bias. For each gene, the 242 difference between each pair of samples from the same tumor were calculated. The median 243 difference between the paired-differences was then taken, yielding a gene-specific, patient-244 specific measure of heterogeneity. This was repeated for all genes, across all tumors, generating 245 a matrix of gene by patient values. Gene intratumor heterogeneity values are summarized as the 246 median value per gene across all tumors in the cohort. Patient intratumor heterogeneity values 247 are summarized as the median value per tumor across all genes. Patient intratumor heterogeneity 248 values represent the expected value of the absolute log2-fold change for a randomly chosen gene 249 within a given tumor.

TCR ITH score is defined as 1 – percentage of shared clonotypes across multiple regions of tumor based on WTS. T cell clones are estimated using MiXCR application on Illumina BaseSpace (<u>http://basespace.illumina.com/apps/</u>). Furthermore, all ITH scores are classified as high versus low using the median as threshold.

254

Distinction between dedicated TCRseq and TCR clones inferred from RNAseq using
 MiXCR

All TCR associated data analysis in this study (including tissue or PBMC) are based on ultra-deep T cell repertoire sequencing (targeted TCRseq) to mitigate undersampling of T cell clones except TCR ITH analysis in Fig. 3b where ITH associated with multiregional sequencing is derived from MiXCR T cell estimates from RNAseq data due to the lack of multiregional TCRseq for all patients.

262

263 ccRCC evolutionary subtypes and intra-tumor DNA Heterogeneity Score

264 DNA ITH score is calculated as the ratio of subclonal to clonal driver genomic alterations 265 including SNVs, INDELs, and SCNA [14]. A genomic alteration is defined to be subclonal if it is 266 present in less than half of the regions collected in each patient. Patients who enough DNA 267 biopsies are collected are classified into 1 of the 7 ccRCC evolutionary subtypes as described 268 before [14]. We used neighbor joining tree construction in ape package in R [38] for reconstruction 269 of tumor clones. TCGA ITH score was obtained from a previous study as measured by the number 270 of clones estimated per sample using PhyloWGS [39]. Briefly, PhyloWGS is a method to infer 271 tumor evolution evolutionary using the relationships between tumor subpopulations based on 272 variant allele frequencies while considering copy number alterations.

273

274 HLA and TCR diversity

275 Shannon entropy is calculated to define TCR diversity [40]. We used MiXCR application 276 on Illumina BaseSpace (<u>http://basespace.illumina.com/apps/</u>) for alignment and T cell clonotype 277 identification. Immunarch (<u>https://immunarch.com/</u>) [41] was used for downstream analysis 278 including visualization and data analysis. Morisita index [42] was used to measure clonotype 279 overlap. HLA diversity index is measured as adopted from [43] as described in [25].

280

281 Neoantigen Depletion

282 The fraction of neoantigens depleted is defined for each sample where pretreatment data 283 was available. We first calculated the neoantigen depletion as the number of neoantigens that 284 were undetectable after therapy but were detected pretreatment. The fraction of neoantigens 285 depleted was then defined as the ratio of the total number of depleted neoantigens over total 286 pretreatment neoantigens. To distinguish neoantigen depletion due to contraction (immune 287 elimination) from evasion, we exclude any neoantigens that were depleted without the presence 288 of HLA LOH (defects in antigen presentation machinery), or reduced expression i.e., log2(FC)< -289 1 where FC is the fold change defined as the ratio of post treatment TPM over pretreatment TPM 290 after correction for tumor purity. Conversely, a neoantigen is annotated as deleted due to immune 291 elimination if log2(FC)>=0 and no HLA LOH was detected. Likewise, HERV editing is defined as 292 the median change in the expression of immunogenic HERVs compared to pre-treatment 293 expression. Immunogenic HERVs refers to HERV loci whose expression strongly correlates with 294 TIL abundance, FDR<0.05.

295

296 Weighted Gene Co-expression Network Analysis (WGCNA) and gene signature extraction

297 We performed WGCNA [44] on all samples where the fraction of neoantigens depleted 298 was available similar to previously described [10]. Briefly, genes with low expression values and 299 invariant genes, that is, genes that were expressed in <5% of samples or had s.d. ≤ 1 for 300 expression (log2 TPM) were filtered together with non-coding genes. The soft power of 6 was 301 chosen based on goodness of fit to a scale-free network. We first annotate modules as JAVELIN 302 or angiogenesis according to the Spearman correlation between the module eigengene and 303 JAVELIN or angiogenesis ssGSEA scores (highest correlation is classified as JAVELIN or 304 angiogenesis module). Likewise, among all modules, the module with the highest Spearman 305 correlation with the fraction of neoantigens depleted was annotated as immune escape module

306 (85 genes). This 85 genes gene signature was strongly associated with PFS of Avelumab plus 307 Axitinib in JAVELIN Renal 101 (HR=1.45, P=0.02, Extended Data Fig. 11a). To further refine this 308 gene signature, we first sorted genes based on their pairwise spearman correlation (Extended 309 Data Fig. 11b) and then selected genes with the highest spearman correlation such that no genes 310 have a spearman correlation <0.6 (Extended Data Fig. 11c). This reduced the number of genes 311 to total of 12 highly correlated genes known as immune escape signature (TIMP1, PXDN, 312 COL15A1, OLFML2B, COL5A2, DLX5, SOX11, KLHDC8A, UNC5A, ADAMTS14, MMP11, FN1). 313 Several genes (ADAMTS14, MMP11, FN1, COL5A1, COL5A2 and TIMP1) in this signature has 314 previously been described as TGF-β-associated extracellular matrix genes that are linked to 315 immune evasion and immunotherapy failure [45].

316

317 Statistical Analysis

All statistical tests were performed in R. To calculate correlations, cor.test with Spearman's method was used. Tests comparing distributions were performed using wilcox.test. All statistical analyses were two-sided and p-values were Benjamini-Hochberg corrected.

321

322

323 **Results**

324 The landscape of microenvironmental ITH in ccRCC

To study ITH in ccRCC, we completed ultra-deep (median coverage of 360X) multiregional whole-exome sequencing and whole-transcriptome sequencing across 142 tumor regions from 29 patients, including 6 untreated and 23 post ICI (see Methods and Table S2). Tumor biopsies were extracted from different regions of the same primary tumor unless specified (Fig. 1a, and b, Table S2). While intra-tumoral genetic heterogeneity in ccRCC is well-

330 described[46], comparatively little is known about the extent of microenvironmental heterogeneity 331 and its relationship to other molecular features of the tumor. To measure the extent of intra-332 tumoral microenvironmental heterogeneity, we leveraged multi-regional WTS of up to 5 regions 333 from 29 patients. Using single sample gene set enrichment analysis (ssGSEA) of established 334 gene signatures, we quantified the expression of several TME gene expression signatures 335 recently proposed as biomarkers of response to ICIs and anti-angiogenic agents [47] (myeloid 336 signature [8], JAVELIN signature [10], and angiogenesis signature, see Methods and 337 Supplementary S3). We confirmed that these RNA signatures accurately quantified the 338 abundance of key immune populations using matched immunofluorescence data, including 339 statistically significant associations between CD31/angiogenesis (p=0.0003), CD8/JAVELIN T 340 cell signature (p = 0.02), and CD68/Myeloid infiltration (p=0.0013) (Fig. S1).

341 Microenvironmental signatures demonstrated extensive heterogeneity across tumor 342 regions from the same patient (Fig. 2a). While a small number of patients showed relatively 343 uniform immune infiltration (e.g., NIVO02, Fig. 2a), the significantly more common phenomenon 344 was for patients to exhibit regions both above and below the median score for a 345 microenvironmental feature of interest (e.g., angiogenesis in MR03, JAVELIN/Teffector 346 signatures in NIVO22). Using the myeloid signature (which has previously been associated with 347 poor response to ICI) as an example, we observed most patients cannot be uniquely classified to 348 myeloid enriched or depleted across all tumor regions (Fig. 2c). Given that several of these 349 signatures are under active investigation as biomarkers of response to ICI, we investigated more 350 generally how classification of regions into high/low was affected by ITH. Remarkably, in more 351 than half of the patients, clinically relevant signatures (Angiogenesis, T-effector, Myeloid, and 352 JAVELIN) could not be consistently classified as high or low (Fig. 2b, 2 patients (MR05 and 353 NIVO10) were excluded since WTS data of only one region was available).

354 We hypothesized elevated microenvironmental heterogeneity may reflect the presence of 355 underlying genomic driver alterations. To test this, we leveraged multi-regional WES data 356 collected for these patients. Frequencies of established ccRCC driver alterations were in 357 agreement with a previous multi-regional study by TRACERx Renal [14] (Fig. 3a). We performed 358 unsupervised hierarchical clustering of major ccRCC driver mutations (i.e., VHL, PBRM1, SETD2, 359 BAP1) and genomic alterations enriched with metastatic disease and ICI response (HLA LOH 360 and CDKN2A/B copy number loss)[37, 43, 48], ultimately identifying two clusters (Fig. 3b, Table 361 S4). We compared the results of these clusters to aggregate, univariate measures of intra-tumoral 362 DNA, RNA, and T-cell receptor (TCR) heterogeneity. Interestingly, one cluster was characterized 363 both by an enrichment of specific genomic alterations (SETD2 mutations, Fisher exact test 364 P=0.002; CDKN2A/B copy number loss, Fisher exact test P=0.0001; HLA LOH, Fisher exact test 365 P=0.0007). This same cluster of patients, which we refer to herein as "ITH-high", had comparable 366 levels of tumor purity to the other "ITH-low" cluster, but demonstrated elevated ITH at the level of 367 somatic DNA alterations, RNA, and TCR (combined Fisher exact test P=0.0495). Moreover, by 368 classifying patients into previously described ccRCC evolutionary subtypes (Fig. S2), we 369 observed that PBRM1-driven tumors were enriched in the ITH-high cluster (on sample level, 370 Fisher exact test P=0.0018), in agreement with TRACERx Renal [14]. However, this finding must 371 be treated with caution due to our relatively small cohort size as well as low number of regions 372 collected in some patients. These findings were robust to the number of regions collected per 373 tumor, and we found no significant association between ITH and exposure to ICI (Fisher exact 374 test P=0.65, Fig. 3b). Together, our results demonstrate (1) that ITH is not restricted to genomic 375 events, but rather is pervasive in the transcriptome, microenvironment, and immune compartment 376 of ccRCC tumors, and (2) correlates with specific somatic events at the level of individual patients 377 (i.e., PBRM1 and SETD2 mutations, HLA LOH and CDKN2A/B loss).

378

379 ITH-high ccRCC tumors are immunologically distinct

380 Comparing the TME characteristics of ITH-high and ITH-low patients, we observed that 381 ITH-high tumors (defined as all regions belonging to a patient who is classified as ITH-high) were 382 characterized by high myeloid and low T cell effector (Teff) signatures (Fig. 3c). Similarly, a 383 signature associated with antigen presentation (APM)[3] was downregulated in ITH-high patients, 384 consistent with elevated levels of HLA LOH in the ITH-high subtype. To validate if genomic 385 features uniquely characterizing ITH-high tumors (HLA LOH and CDKN2A/B loss) might be more 386 generally associated with myeloid infiltration in a large, independent cohort, we obtained DNA 387 and RNA sequencing data from the TCGA KIRC study and scored samples by the presence of 388 CDKN2A/B loss, ITH (as measured by the number of clones estimated per sample using 389 PhyloWGS, see Methods), and myeloid infiltration. This analysis confirmed that in ccRCC, 390 CDKN2A/B loss was associated with higher levels of ITH (P=3x10⁻⁵) and higher myeloid infiltration 391 (P=7x10⁻⁵) (Fig. 3d). However, the association between genomic ITH and myeloid infiltration did 392 not reach statistical significance in TCGA KIRC cohort suggesting the association between 393 myeloid infiltration and ITH is likely indirect through certain genomic events such as CDKN2A/B 394 loss.

395 The findings above suggested that ITH-high tumors may be distinct in their 396 immunophenotype, including in the diversity of their T cell repertoire. We therefore investigated 397 the association between ITH and T cell diversity both peripherally and within the tumor. To do so. 398 we compared the overlap between tissue-resident and peripheral T cells. Repertoire overlap 399 analysis (Fig. S3) illustrated a high degree of shared clonotypes across different tumor regions 400 from the same patient, but a lack of shared clonotypes across patients. ITH-high patients 401 demonstrated a significantly lower peripheral TCR diversity, richness and clone count compared 402 to ITH-low patients (Fig. 3e), suggesting that elevated heterogeneity in the primary tumor is 403 associated with reduced peripheral immunologic diversity in a manner that is consistent with

404 reports in other diseases [49]. To allow a fair comparison of samples with different number of T 405 cells and account for TCR subsampling, we also studied rarefaction curves and estimated TCR 406 diversity by sequentially resampling TCR clonotypes and computing mean number of unique 407 clones [50]. Estimated diversity using rarefaction curves led to a similar conclusion confirming the 408 observed differences in the TCR diversity are unlikely to be due to artifacts in T cell subsampling 409 (Fig. S3b). Together, the above data argue that elevated molecular heterogeneity in ccRCC 410 tumors is associated with a distinct microenvironmental and immunologic phenotype.

411

412 ICI therapy is associated with loss of putative neoantigens and HLA LOH

413 The clinical management of ccRCC (for which pre-surgical biopsies are often not indicated 414 or used) makes serial profiling of primary tumors on therapy challenging, rendering our 415 understanding of how ICI may remodel tumor physiology incomplete. To overcome this challenge, 416 we took advantage of 16 patients from our neoadjuvant nivolumab clinical trial who had WES 417 performed on their pre-treatment biopsies. This offered a unique opportunity to interrogate both 418 genomic adaptations (including both somatic mutations as well as the expression of potentially 419 immunogenic endogenous retroviral elements, HERVs) to ICI therapy, as well as immunologic 420 changes in the T cell repertoire.

421 Focusing first on genetic alterations, we anticipated that ICI administration would lead to 422 elimination of some tumor clones and therefore a contraction in total mutation count. However, 423 we observed no consistent trend in the change of either SNV or indel mutational count following 424 ICI therapy (Fig. S4). Nevertheless, the number of non-synonymous SNVs that were predicted to 425 bind to MHC complex in silico was consistently reduced across all patients and all biopsies except 426 for NIVO03 (Fig. S4 and Fig. 4a). An opposite trend was observed in the number of putative non-427 binders, suggesting a selection in favor of non-neoantigenic mutations by tumor during clonal 428 evolution (Fig. 4a).

429 In order to characterize the clonality of putative neoantigen depletion across distinct tumor 430 regions, we counted all 8-11 amino-acid-long putative neoantigens seen prior to treatment but 431 deleted in at least one biopsy after treatment. Among 7 patients with at least 4 tumor regions 432 sequenced, we observed an enrichment for putative neoantigen depletion across 4 or more sites 433 (Fig. 4b). Focusing on patient NIVO20, all 6 identified depleted putative neoantigens were deleted 434 in at least 4 regions, suggesting putative neoantigen depletion is a clonal event (Fig. 4c). Genes 435 expressing these depleted neoantigens demonstrated a 2-3-fold reduction in expression related 436 to pre-treatment biopsy (NIVO20-RA/RB/RC/RD/RE vs NIVO20-BX) (Fig. 4d). Together with the 437 data above, these observations suggest that ICI therapy in ccRCC is associated with the clonal 438 loss of mutations with elevated immunogenicity.

Premised on prior reports [51] of the increased immunogenicity of hydrophobic residues, we sought to determine whether a selective pressure exists on certain neoantigens. We compared the number of amino acids preserved versus depleted upon immunotherapy, and noticed a strong selection against Phenylalanine (F, extremely hydrophobic) in favor of Arginine (R, extremely hydrophilic) and Glutamic acid (E, extremely hydrophilic) in our cohort (Fig. 4e).

444 We next examined the magnitude of putative neoantigen depletion in each patient by 445 measuring the average number of putative neoantigens deleted per biopsy (i.e., the ratio of the 446 deleted neoantigens in a treated region compared to pre-treatment over the total number of pre-447 treatment neoantigens). We observed that the fraction of neoantigens depleted was strongly 448 associated with myeloid-high regions (n = 16 patients whose pre-ICI treatment WES data was 449 available, Fig. 4f). The association between myeloid activation and neoantigen depletion 450 remained strong when total number of neoantigens depleted was used (instead of fraction) (Fig. 451 S5b) or when putative neoantigen (transcriptional) expression was taken into account (n = 7452 patients whose pre-treatment WTS data was available, Fig. 4g) and was not affected by variation 453 in tumor purity (Fig. S5). Furthermore, the correlation between the degree of neoantigen depletion

and myeloid infiltration was also evident when examining different regions of individual patients,
where highly depleted regions were associated with the highest myeloid and lowest ImmuneScore
(Fig. 4g).

457 A recent study [52] identified tumor infiltrating lymphocyte specific HERV epitopes that are 458 translated, can bind to MHC I complex, and induce high-avidity cytotoxic T cells. In [52] as well 459 as other previous reports [53], over expression of HERVs on tumor cells has been reported and 460 a link to ICI response has been documented [54]. To interrogate other tumor intrinsic features 461 associated with immune response in our cohort we utilized our deep RNA sequencing (~200 462 millions read/library) to guantify HERV expression. HERVs were overexpressed in tumors 463 compared to normal tissues in our cohort (Fig. 4h), and median HERV (median of all HERV loci 464 investigated) was correlated to angiogenic expression (Fig. S7a). Notably, PBRM1 mutations, 465 which lead to further HIF upregulation [55] and angiogenic expression [56, 57], were also 466 positively associated with HERV (Fig. S7b), consistent with a recent report [58]. In agreement 467 with [54] we then confirmed the association between the median expression of different HERV 468 loci and TIL abundance (Fig. S7a). Median HERV was anti-correlated with tumor purity; however, 469 the association between HERV expression and TIL abundance remained valid even when HERV 470 expression was corrected for tumor purity (Fig. S7a). Conversely, we observed a significant 471 reduction in HERV expression an observation akin to reduction in neoantigens (Fig. 4i). Likewise, 472 we observed a strong correlation between HERV editing (i.e., change in the expression of 473 immunogenic HERV loci after treatment, see Methods) and myeloid signature further highlighting 474 the association between neoantigen depletion and myeloid enrichment (Fig. 4). Due to the 475 limitations of HERV quantification using WTS, we could not rule out that a strong correlation 476 between HERV and TIL abundance might be due to expression of HERV on immune cells. 477 However, the expression of HERV on ccRCC tumor cells has been previously shown [59] and 478 their immunogenicity is well-established [52]. Nevertheless, rigorous determination in future

studies of cell-specific expression of HERVs will be critical to understanding their putativeassociation with ICI response.

481 Finally, using TCRseg of tissue resident and peripheral T cells, we investigated the impact 482 of ICI and neoantigen depletion on T cell diversity. Focusing again on patient NIVO20 where TCR 483 data of multiple regions of pre-treatment and ICI treated tumor were available, we evaluated the 484 degree of overlap between T cell clonotypes at different regions and time points i.e., pre-485 treatment, on-therapy, and post ICI treatment (Fig. 4k). Tracking dominant tissue resident T cell 486 clonotypes, we noticed a substantial depletion of dominant T cell clones upon ICI therapy (Fig. 487 4k). This observation was mirrored across our entire cohort, where we observed a strong negative 488 association between peripheral TCR diversity and neoantigen depletion and allele specific HLA 489 loss across the entire cohort where PBMC TCRseq data was collected (Fig. 4I, m). Together, if 490 validated using future mechanistic experiments, our findings suggest that neoantigen depletion in 491 primary ccRCC tumors is associated with peripheral loss of neoantigen reactive T cells. However, 492 at this point, no causal relationship between neoantigen loss and TCR diversity can be drawn.

493

494 Subclonal evolution underlies immune escape

495 In order to understand the immunologic mechanisms driving subclonal evolution after ICI. 496 we investigated in detail patients whose tumors underwent subclonal immunoediting in distinct 497 regions. Strikingly, subclonal reconstruction revealed recurrent subclonal evolution of HLA LOH 498 and CDKN2A/B loss following ICI therapy (Fig. 5a). Notably, we observed HLA LOH and 499 CDKN2A/B loss co-occur in 9 patients (Fisher exact test P=0.003) and most tumor regions (Fisher 500 exact $P=5\times10^{-7}$) (Fig. 5b). Strikingly, comparing the untreated and treated regions, we only 501 observed a significant immunological response (as measured by Th1 response) in regions without 502 CDKN2A/B loss or HLA LOH (Fig. 5c), suggesting that HLALOH or CDKN2A/B loss are subclonal 503 determinants of response to ICI [37, 43, 48]. This is consistent with recently published data [49]

indicating the loss of 9p21 - encompassing CDKN2A/B – confers a cold tumor immune microenvironment and resistance to ICI. In that study, Han *et al.* [49] linked 9p21 loss to a decreased abundance of B, T, CD8 T, NK cells and cytotoxic lymphocytes, and an increased fractions of macrophages, as well as reduced TCR CDR3 repertoire abundance and diversity. We interpret our observations to mean that immuno-editing occurs under selective pressure by which certain tumor subclones transform to a less immunogenic phenotype through HLA LOH and CDKN2A/B loss, and that this subclonal selection can produce a highly heterogenous TME.

511 To further shed light on the how tumor evolution can transform TME, we sought to analyze 512 the spatial distribution of TILs within the TME and their interaction with the stromal compartment 513 using immunohistochemical data. Following A.W. Zhang and colleagues [60], a dedicated 514 genitourinary pathologist classified tumor regions into 3 subtypes according to the co-localization 515 of tumor infiltrating lymphocytes and tumor cells: N-TIL (tumors sparsely infiltrated by TILs), S-516 TIL (tumors dominated by stromal TILs), and ES-TIL (tumors with substantial levels of both 517 epithelial and stromal TILs) (Fig. 5d). We observed that an ES-TIL enriched TME is strongly 518 associated with regions with HLA LOH (ES=4, N=7, S=5 compared to ES=2, N=32, S=21 in HLA 519 intact regions, Fisher's exact test P = 0.036) or loss of CDKN2A/B (ES=4, N=7, S=9 compared to 520 ES=2, N=32, S=17 in regions without loss of CDKN2A/B, Fisher's exact test P = 0.03) whereas 521 N-TIL pathology is linked with regions with no HLA LOH and no CDKN2A/B loss across the cohort. 522 These findings suggest that despite abundant TILs, post-ICI ES-TIL are associated with tumor 523 clones that have evolved genetic mechanisms for evasion of the immune response (HLA LOH 524 and/or CDKN2A/B loss). However, future mechanistic studies are needed to pinpoint the primary 525 genomic event that transforms the ccRCC TME into a cold niche.

526

527 An adverse ccRCC TME is enriched stroma and myeloid signatures

528 We hypothesized that neoantigen depletion could be associated with a specific 529 transcriptional signature, akin to those identified in clinical trial settings as biomarkers for 530 response to ICI in ccRCC. To identify such a signature, we performed unsupervised Weighted 531 Gene Co-expression Network Analysis (WGCNA) [44] to reconstruct modules from our 532 transcriptomic samples similar to [10] (Fig. 6a). Reassuringly, we identified two gene expression 533 modules #7 and #4 reflecting established microenvironmental features associated with 534 therapeutic response in ccRCC: immune inflammatory response ("JAVELIN-like" signature) and 535 "angiogenesis-like" (Fig. 6a, b). We next assessed the correlation between the expression of each 536 WGCNA gene module and neoantigen depletion. While the JAVELIN-like and angiogenesis-like 537 modules showed no association with neoantigen depletion, module 16 demonstrated the 538 strongest association (Fig. 6a). Correlation analysis with previously known gene expression 539 signatures illustrated that module 16 (which we refer to as an "Immune Escape" signature) was 540 strongly associated with myeloid and stroma features of TME. The Immune Escape signature 541 also resembled a recently described pan-cancer TGF β signature derived in a previous study [45] 542 which was linked to cancer-associated fibroblasts enriched in immune evasion and 543 immunotherapy failure. However, no association between the Immune Escape signature and 544 treatment status was observed (Wilcox P=0.79) (Fig. S8).

545 To reveal the primary cellular populations driving the Immune Escape signature in the 546 ccRCC TME, we leveraged scRNAseq from multiple tumor regions, lymph node, normal kidney, 547 and peripheral blood of two ICI-naïve and four ICI-treated patients [15] (n=167283 single cells) 548 (Fig. 1c). We identified 28 clusters (Fig. 6c) using Louvain clustering [61, 62] and each cluster 549 was annotated based on our previous study [15]. As expected, scRNAseq revealed enrichment 550 of this signature in renal epithelium, tumor stroma as well as tumor associated macrophages 551 (TAMs) and monocytes (Fig. 6c). Hence, both scRNAseg and histopathological evaluation further 552 confirmed the association between Immune Escape and neoantigen depletion (Fig. 6a, Spearman

553 correlation = 0.6), ITH (Fig. 6d, Wilcox P=0.003), myeloid activation (Fig. 6b, Spearman 554 correlation = 0.8) and with stroma, and renal epithelium histopathology (Fig. 5d and Fig. 6e, f).

555

556 Immune Escape correlates with clinical outcome to ICI therapy

557 Several previous studies have associated signatures of Immune Escape with poor clinical 558 outcome in ICI treated patients [63]. Thus, we evaluated whether our Immune Escape signature 559 can correlate with clinical outcome to ICI treatment. We obtained publicly available RNAseg data 560 for several clinical trials including phase 3 JAVELIN Renal 101 trial [10] – a phase III randomized 561 anti-PD-L1 (avelumab) plus tyrosine kinase inhibitor (TKI, axitinib) versus multi-target TKI 562 (sunitinib), IMmotion151 [64] - a phase III trial comparing anti-PDL1 (atezolizumab) plus anti-563 angeniogenesis agent (bevacizumab) versus TKI (sunitinib) in first-line metastatic renal cell 564 carcinoma, CheckMate 009/010 - a phase I/II, aPD-1 (nivolumab) treated, and CheckMate 025 -565 a phase III randomized mTOR inhibitor (everolimus) versus aPD-1 [9]. We stratified patients by 566 the median score (see Methods) of the 3 gene signatures obtained in our study (i.e., module 567 4/JAVELIN like, 7/angiogenesis-like, and 16/immune escape.

568 The Immune Escape signature was strongly associated with the response to all three ICI 569 regimens (avelumab plus axitinib HR=1.53 P=0.008, atezolizumab plus bevacizumab HR=1.35 570 P=0.019 and nivolumab HR=1.45 P=0.02, Fig. 7 and Fig. S9). In contrast, the JAVELIN-like 571 inflammatory signature was strongly associated with clinical outcome to avelumab plus axitinib 572 (HR=0.64 P=0.006), but no association with clinical benefit was found between atezolizumab plus 573 bevacizumab (HR=0.82 P=0.126) or nivolumab treatment (HR=0.97 P=0.823) (Fig. 7). Similarly, 574 the angiogenesis-like signature was strongly correlated with the response to sunitinib in both 575 IMmotion151 (HR=0.48 P<0.001) and JAVELIN Renal 101 (HR=0.68 P=0.008) as expected, but 576 not with ICI-associated regimens. Associations between the Immune Escape signature and 577 therapeutic response remained valid even when thresholds other than median were used to

define immune escape high and low (Fig. S10). Even though the Immune Escape signature was also associated with response to sunitinib in JAVELIN Renal 101, no association between sunitinib response or mTOR inhibition was observed in IMmotion151 and CheckMate 025. Overall, this analysis suggests that a transcriptional signature associated the tendency to lose putative neoantigens after ICI is associated with response to combination ICI therapy and nominates a new potential biomarker for this therapeutic regimen.

584

585 **Discussion**

586 Here we used spatiotemporal, multimodal profiling to investigate the link tumor genomics, 587 microenvironmental heterogeneity, peripheral immune response, and eventual immune escape 588 in advanced and metastatic ccRCC. The fundamental discovery of our analysis is that ITH 589 manifests well beyond the tumor genome and produces highly heterogeneous immune 590 microenvironments in the tumor. Our findings clearly suggest that the ccRCC genome and 591 microenvironment co-evolve, and that loss of putative neo-antigens (including SNVs, indels, and 592 HERVs) is associated with a qualitatively myeloid-high environment and the loss of HLA and 593 CDKN2A/B. These distinct genomic alterations are also associated with more peripheral changes. 594 i.e., reduced T cell clonal diversity in the peripheral circulation.

595 Emerging data on biomarkers of response to ICI in ccRCC has identified two potentially 596 paradoxical observations: first, that TIL abundance alone is an insufficient predictor of ICI 597 response [9], and second, that the presence of myeloid cells correlate with resistance to both ICI 598 and anti-VEGF treatments. Strikingly, we observed that high myeloid score tumors were 599 associated with neoantigen depletion which could, in principle, render ICI treatment ineffective. In 600 agreement with this, we derived a transcriptomic signature associated with neoantigen depletion 601 and Immune Escape, which was expressed in renal epithelium, tumor stroma as well as tumor 602 associated macrophages (TAMs) and monocytes. This Immune Escape signature was associated

with response to several ICI regiments in published clinical trials. In total, these findings suggest that myeloid cells are associated with tumor clones that have evolved mechanisms to escape anti-tumor immune responses. Critically, such a hypothetic model requires detailed work and mechanistic validation in immunocompetent systems, which we are actively developing.

607 Why do regions with neoantigen depletion demonstrate elevation of myeloid cells but not 608 cytotoxic T cells that would presumably eliminate tumor clones? Cancer immunoediting proceeds 609 through three phases: elimination, equilibrium and escape [65]. Throughout these phases, tumor 610 immunogenicity evolves, and thereby, despite possible initial response to therapy, acquires 611 immunosuppressive mechanisms that may enable disease progression. Our data suggests that 612 myeloid-high, neoantigen-depleted tumor regions historically experienced a cytotoxic T cell 613 response, which prompted the selection of tumor clones losing neoantigens and/or 614 HLA/CDKN2A/B. Such a loss of target antigens through HLA LOH or neoantigen depletion would 615 result in loss of antigen-TCR stimulation, leading to death of the corresponding neoantigen 616 reactive T cells (Fig. 8). Importantly, as with other findings in this analysis, the association 617 between neoantigen loss and myeloid activation observed in our data remains purely correlative, 618 and future studies will be necessary to mechanistically establish how immune evasion 619 spatiotemporally evolves in ccRCC following ICI therapy.

620 Our multi-regional data also has significant implications for biomarker development. We 621 demonstrated that TME markers of response such as JAVELIN and myeloid scores can be 622 heterogenous within tumors regions (Fig. 2). This underscores the importance of accounting for 623 ITH when these signatures are used for patient selection for a specific therapy and longitudinal 624 monitoring of therapies. Given recent data that ICI may have a role in adjuvant therapy following 625 nephrectomy for high-risk disease, our data would suggest that several regions of the primary 626 tumor should be sampled specially in the presence of ITH associated genomic alterations (e.g., 627 HLA LOH and CDKN2A/B loss). An intriguing finding was a trend towards lower ITH in ICI treated

628 tumors, even though this observation did not reach statistical significance. If validated in other 629 studies, this in part can be attributed to outgrowth of few non-immunogenic tumor subclones that 630 managed to escape immune surveillance upon ICI treatment.

631 An important limitation of this study is that TME heterogeneity of metastatic disease was 632 not assessed and may be less of an issue in biomarker development. Our study has several other 633 potential limitations including its small sample size. To overcome this shortcoming, we validated 634 several of our major findings in several independent cohorts. Another potential limitation of our 635 study is the unavailability pre-treatment multi-regional sequencing data. However, inclusion of 636 multi-regional data from 6 untreated patients allowed us to account for ITH in untreated tumors. 637 Moreover, our neoadjuvant cohort was treated with single agent nivolumab over a short course 638 which may not reflect the TME, and genomic changes induced by more potent combination 639 strategies. Finally, we portrayed the characteristics of an adverse TME which may contribute to 640 ICI resistance. Our study clearly demonstrates the interplay between genomic events and TME 641 transformation from a cytotoxic to a cold immuno-phenotype. However, these findings remain 642 purely an association of several contributing factors to ICI resistant and the exact causative 643 hierarchy of events requires further investigation.

In conclusion, we find distinct genomic event enriched in immune escape tumor microenvironment in ccRCC both across and within tumors. Our findings have implications for future biomarker development for ICI response across ccRCC and other solid tumors.

647

648 Availability of data and materials

No new code was generated. All data generated in this study are provided in Extended Data Tableand Figures or available upon reasonable request from corresponding author.

651

652 Abbreviations

- **TCGA**: The Cancer Genome Atlas
- **WES**: Whole-exome sequencing
- **WTS**: Whole-transcriptome sequencing
- **SCNA**: Somatic copy number alterations
- 657 LOH: Loss of heterozygosity
- 658 ITH: Intra-tumoral heterogeneity
- 659 TCR: T cell receptor
- *ccRCC*: clear cell Renal Cell Carcinoma
- **TME**: Tumor microenvironment
- *ICI*: Immune checkpoint inhibitor
- 663 TKI: Tyrosine kinase inhibitor
- *HERV*: Human endogenous retrovirus
- **PBMC**: peripheral blood mononuclear cells
- **TIL**: Tumor infiltrating lymphocytes
- **WGCNA**: Weighted gene co-expression network analysis
- **ssGSEA**: single sample gene set enrichment analysis

- 671 References
- Liu X-D, Hoang A, Zhou L, Kalra S, Yetil A, Sun M, Ding Z, Zhang X, Bai S, German P:
 Resistance to antiangiogenic therapy is associated with an immunosuppressive

(74		tumo a miano antina moto toto a statio negali calli consistenza. O successive menerale me
6/4		tumor microenvironment in metastatic renai cell carcinoma. Cancer immunology
0/5	0	research 2015, 3:1017-1029.
6/6	2.	Rooney MS, Shukla SA, Wu CJ, Getz G, Haconen N: Molecular and genetic
6//		properties of tumors associated with local immune cytolytic activity. Cell 2015,
678	-	160: 48-61.
679	3.	Şenbabaoğlu Y, Gejman RS, Winer AG, Liu M, Van Allen EM, de Velasco G, Miao D,
680		Ostrovnaya I, Drill E, Luna A: Tumor immune microenvironment characterization in
681		clear cell renal cell carcinoma identifies prognostic and immunotherapeutically
682		relevant messenger RNA signatures. Genome biology 2016, 17:1-25.
683	4.	Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA,
684		Postow MA, Wong P, Ho TS: Genetic basis for clinical response to CTLA-4
685		blockade in melanoma. New England Journal of Medicine 2014, 371:2189-2199.
686	5.	Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt
687		C, Luber BS: Mismatch repair deficiency predicts response of solid tumors to PD-1
688		blockade. Science 2017, 357:409-413.
689	6.	Samstein RM. Lee C-H. Shoushtari AN. Hellmann MD. Shen R. Janiigian YY. Barron
690		DA. Zehir A. Jordan EJ. Omuro A: Tumor mutational load predicts survival after
691		immunotherapy across multiple cancer types. <i>Nature genetics</i> 2019, 51 :202-206.
692	7	Havel JJ Chowell D Chan TA: The evolving landscape of biomarkers for
693	••	checkpoint inhibitor immunotherapy Nature Reviews Cancer 2019 19 :133-150
694	8	McDermott DE Huseni MA Atkins MB Motzer R.I. Rini BI Escudier B Fong L. Josenh
695	0.	RW Pal SK Reeves IA: Clinical activity and molecular correlates of response to
696		atezolizumab alone or in combination with bevacizumab versus sunitinib in renal
607		coll carcinoma. Natura modicina 2018 21 :740 757
608	0	Broup DA Hou V Bakeupy 7 Fisial M Sant'Angola M Forman I Bass Macdonald B
600	9.	Braun DA, nou T, Bakouny Z, Ficial W, Sant Angelo W, Forman J, Ross-Macuonau F,
700		infiltration modulates response to DD 1 blockeds in advanced clear cell rend cell
700		annihation modulates response to PD-1 blockade in advanced clear cen renar cen
701	10	Carcinoma. Nature medicine 2020, 20:909-910.
702	10.	Molzer RJ, Robbins PD, Powies T, Albiges L, Haanen JD, Larkin J, Mu AJ, Ching RA,
703		Oemura IVI, Pal SK. Avenumab plus axiumb versus sumumb in advanced renai cen
704		carcinoma: Biomarker analysis of the phase 3 JAVELIN Renal 101 that. Nature
705		medicine 2020, 26 :1733-1741.
/06	11.	Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS,
/0/		Sosman JA, Procopio G, Plimack ER: Nivolumab versus everolimus in advanced
/08	4.0	renal-cell carcinoma. New England Journal of Medicine 2015, 373:1803-1813.
709	12.	Yarchoan M, Hopkins A, Jaffee EM: Tumor mutational burden and response rate to
/10		PD-1 inhibition. The New England journal of medicine 2017, 377:2500.
711	13.	Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B,
712		Soulières D, Melichar B: Pembrolizumab plus axitinib versus sunitinib for advanced
713		renal-cell carcinoma. New England Journal of Medicine 2019, 380:1116-1127.
714	14.	Turajlic S, Xu H, Litchfield K, Rowan A, Horswell S, Chambers T, O'Brien T, Lopez JI,
715		Watkins TB, Nicol D: Deterministic evolutionary trajectories influence primary
716		tumor growth: TRACERx renal. Cell 2018, 173:595-610. e511.
717	15.	Krishna C, DiNatale RG, Kuo F, Srivastava RM, Vuong L, Chowell D, Gupta S,
718		Vanderbilt C, Purohit TA, Liu M: Single-cell sequencing links multiregional immune
719		landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy
720		efficacy. Cancer Cell 2021.
721	16.	Au L, Hatipoglu E, de Massy MR, Litchfield K, Beattie G, Rowan A, Schnidrig D,
722		Thompson R, Byrne F, Horswell S: Determinants of anti-PD-1 response and
723		resistance in clear cell renal cell carcinoma. Cancer cell 2021, 39:1497-1518. e1411.

724 725 726	17.	Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M, Gingeras TR: STAR: ultrafast universal RNA-seq aligner. <i>Bioinformatics</i> 2013, 29: 15-21
727 728	18.	Lawrence M, Huber W, Pages H, Aboyoun P, Carlson M, Gentleman R, Morgan MT, Carey VJ: Software for computing and annotating genomic ranges. <i>PLoS Comput</i>
729	10	Biol 2013, 9:e1003118.
730 731 722	19.	M, Sugnet CW, Thomas DJ: The UCSC genome browser database. Nucleic acids
732	20	Tesearch 2003, 31:51-54.
734	20.	for RNA-seg data with DESeg2 Genome biology 2014 15:1-21
735	21	Yoshihara K Shahmoradgoli M Martínez E Vegesna R Kim H Torres-Garcia W
736		Treviño V. Shen H. Laird PW. Levine DA: Inferring tumour purity and stromal and
737		immune cell admixture from expression data. Nature communications 2013. 4:1-11.
738	22.	Barbie DA. Tamavo P. Boehm JS. Kim SY. Moody SE. Dunn IF. Schinzel AC. Sandy P.
739		Meylan E, Scholl C: Systematic RNA interference reveals that oncogenic KRAS-
740		driven cancers require TBK1. Nature 2009, 462:108-112.
741	23.	Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M,
742		Alizadeh AA: Robust enumeration of cell subsets from tissue expression profiles.
743		Nature methods 2015, 12: 453-457.
744	24.	Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H,
745		Fredriksen T, Lafontaine L, Berger A: Spatiotemporal dynamics of intratumoral
746		immune cells reveal the immune landscape in human cancer. Immunity 2013,
747		39: 782-795.
748	25.	Golkaram M, Salmans ML, Kaplan S, Vijayaraghavan R, Martins M, Khan N, Garbutt C,
749		Wise A, Yao J, Casimiro S: HERVs establish a distinct molecular subtype in stage
750		II/III colorectal cancer with poor outcome. NPJ genomic medicine 2021, 6:1-11.
751	26.	Li H, Durbin R: Fast and accurate short read alignment with Burrows–Wheeler
752	07	transform. <i>bioinformatics</i> 2009, 25 :1754-1760.
753	27.	McKenna A, Hanna M, Banks E, Sivachenko A, Cibulskis K, Kernytsky A, Garimella K,
/54		Altshuler D, Gabriel S, Daly M: The Genome Analysis Toolkit: a MapReduce
133		tramework for analyzing next-generation DNA sequencing data. Genome research
/30	20	2010, 20:1297-1303. DeBriete MA Banka E Banlin B. Carimalle KV/ Maguira IB. Hartl C. Bhilinnakia AA. Bal
759	20.	Depristo MA, Barris E, Popilit R, Garinella KV, Maguire JR, Harti C, Philippakis AA, Der
750		Angel G, Rivas MA, Hanna M. A framework for variation discovery and genotyping
759	20	Kebeldt DC, Zhang O, Larson DE, Shan D, Mel allan MD, Lin L, Miller CA, Mardis EP
761	29.	Ding L. Wilson PK: VarScan 2: sometic mutation and convinumber alteration
762		discovery in cancer by exome sequencing. Genome research 2012 22:568-576
762	30	Kim S. Scheffler K. Halpern Al. Bekritsky MA. Noh F. Källberg M. Chen X. Kim V.
764	00.	Bevter D. Krusche P: Strelka2: fast and accurate calling of germline and somatic
765		variants Nature methods 2018 15:591-594
766	31	Rimmer A Phan H Mathieson I Jobal Z Twigg SR Wilkie AO McVean G Lunter G
767	01.	Integrating mapping-, assembly-and haplotype-based approaches for calling
768		variants in clinical sequencing applications. Nature genetics 2014. 46:912-918.
769	32.	Larson DE, Harris CC, Chen K, Koboldt DC, Abbott TE, Dooling DJ, Ley TJ, Mardis ER,
770		Wilson RK, Ding L: SomaticSniper: identification of somatic point mutations in
771		whole genome sequencing data. Bioinformatics 2012, 28:311-317.
772	33.	Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S,
773		Chiotti KE, McLellan M: Scalable open science approach for mutation calling of

774 775		tumor exomes using multiple genomic pipelines. Cell systems 2018, 6:271-281.
776	34	McLaren W. Gil I. Hunt SF. Riat HS. Ritchie GR. Thormann A. Elicek P. Cunningham F:
777	01.	The ensembl variant effect predictor. Genome biology 2016 17:1-14
778	35	Amemiva HM Kundaje A Boyle AP ⁻ The ENCODE blacklist: identification of
779	00.	problematic regions of the genome. Scientific reports 2019 9:1-5
780	36.	Shen R. Seshan VE: FACETS: allele-specific copy number and clonal heterogeneity
781		analysis tool for high-throughput DNA sequencing. Nucleic acids research 2016.
782		44: e131-e131.
783	37.	McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TB, Wilson GA, Birkbak NJ,
784		Veeriah S, Van Loo P, Herrero J: Allele-specific HLA loss and immune escape in
785		lung cancer evolution. Cell 2017, 171:1259-1271. e1211.
786	38.	Paradis E, Claude J, Strimmer K: APE: analyses of phylogenetics and evolution in R
787		language. Bioinformatics 2004, 20:289-290.
788	39.	Raynaud F, Mina M, Tavernari D, Ciriello G: Pan-cancer inference of intra-tumor
789		heterogeneity reveals associations with different forms of genomic instability.
790		PLoS genetics 2018, 14: e1007669.
791	40.	Wu TD, Madireddi S, de Almeida PE, Banchereau R, Chen Y-JJ, Chitre AS, Chiang EY,
792		Iftikhar H, O'Gorman WE, Au-Yeung A: Peripheral T cell expansion predicts tumour
793		infiltration and clinical response. Nature 2020, 579:274-278.
794	41.	Nazarov V: immunarch. bot & Eugene Rumynskiy. immunomind/immunarch: 0.6. 5:
795		Basic single-cell support. Zenodo; 2020.
796	42.	Horn HS: Measurement of overlap in comparative ecological studies. The
797	40	American Naturalist 1966, 100: 419-424.
798	43.	Chowell D, Krishna C, Pierini F, Makarov V, Rizvi NA, Kuo F, Morris LG, Riaz N, Lenz
/99		IL, Chan TA: Evolutionary divergence of HLA class I genotype impacts efficacy of
800	4.4	cancer immunotherapy. Nature medicine 2019, 25:1715-1720.
801	44.	Langleider P, Horvauri S. WGCNA: an R package for weighted correlation network
802 803	15	Chakravarthy A Khan L Bonslor NP Boso P Do Carvalho DD: TCE-B-associated
803	43.	extracellular matrix genes link cancer-associated fibroblasts to immune evasion
805		and immunotherapy failure Nature communications 2018 9:1-10
806	46	Turailic S Xu H Litchfield K Rowan A Chambers T Lonez II Nicol D O'Brien T Larkin
807	40.	.1 Horswell S: Tracking cancer evolution reveals constrained routes to metastases:
808		TRACERx renal. <i>Cell</i> 2018. 173 :581-594. e512.
809	47.	Hakimi AA. Voss MH. Kuo F. Sanchez A. Liu M. Nixon BG. Vuong L. Ostrovnava I. Chen
810		Y-B, Reuter V: Transcriptomic profiling of the tumor microenvironment reveals
811		distinct subgroups of clear cell renal cell cancer: data from a randomized phase III
812		trial. Cancer discovery 2019, 9:510-525.
813	48.	Horn S, Leonardelli S, Sucker A, Schadendorf D, Griewank KG, Paschen A: Tumor
814		CDKN2A-associated JAK2 loss and susceptibility to immunotherapy resistance.
815		JNCI: Journal of the National Cancer Institute 2018, 110 :677-681.
816	49.	Han G, Yang G, Hao D, Lu Y, Thein K, Simpson BS, Chen J, Sun R, Alhalabi O, Wang
817		R: 9p21 loss confers a cold tumor immune microenvironment and primary
818		resistance to immune checkpoint therapy. Nature communications 2021, 12:1-19.
819	50.	Laydon DJ, Bangham CR, Asquith B: Estimating T-cell repertoire diversity:
820		limitations of classical estimators and a new approach. Philosophical Transactions
821	- 4	of the Royal Society B: Biological Sciences 2015, 370 :20140291.
822	51.	Riley TP, Keller GL, Smith AR, Davancaze LM, Arbuiso AG, Devlin JR, Baker BM:
823		Structure based prediction of neoantigen immunogenicity. Frontiers in immunology
824		2019, 10: 2047.

825 52. Bonaventura P, Alcazer V, Mutez V, Tonon L, Martin J, Chuvin N, Michel E, Boulos RE,
826 Estornes Y, Valladeau-Guilemond J: Identification of shared tumor epitopes from
827 endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer
828 immunotherapy. Science Advances 2022, 8:eabj3671.

- Panda A, de Cubas AA, Stein M, Riedlinger G, Kra J, Mayer T, Smith CC, Vincent BG,
 Serody JS, Beckermann KE: Endogenous retrovirus expression is associated with
 response to immune checkpoint blockade in clear cell renal cell carcinoma. *JCI insight* 2018, 3.
- Smith CC, Beckermann KE, Bortone DS, De Cubas AA, Bixby LM, Lee SJ, Panda A,
 Ganesan S, Bhanot G, Wallen EM: Endogenous retroviral signatures predict
 immunotherapy response in clear cell renal cell carcinoma. The Journal of clinical
 investigation 2019, 128:4804-4820.
- 837 55. Nargund AM, Pham CG, Dong Y, Wang PI, Osmangeyoglu HU, Xie Y, Aras O, Han S,
 838 Oyama T, Takeda S: The SWI/SNF protein PBRM1 restrains VHL-loss-driven clear
 839 cell renal cell carcinoma. *Cell reports* 2017, 18:2893-2906.
- 840 56. Hakimi AA, Attalla K, DiNatale RG, Ostrovnaya I, Flynn J, Blum KA, Ged Y, Hoen D,
 841 Kendall SM, Reznik E: A pan-cancer analysis of PBAF complex mutations and their
 842 association with immunotherapy response. Nature communications 2020, 11:1-11.
- Liu X-D, Kong W, Peterson CB, McGrail DJ, Hoang A, Zhang X, Lam T, Pilie PG, Zhu H,
 Beckermann KE: PBRM1 loss defines a nonimmunogenic tumor phenotype
 associated with checkpoint inhibitor resistance in renal carcinoma. Nature
 communications 2020, 11:1-14.
- 58. Zhou M, Leung JY, Gessner KH, Hepperla AJ, Simon JM, Davis IJ, Kim WY: PBRM1
 inactivation promotes upregulation of human endogenous retroviruses in a HIFdependent manner. Cancer immunology research 2022.
- Solution
 Sol
- 854 60. Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T,
 855 Little N, de Souza CP, Laan S: Interfaces of malignant and immunologic clonal
 856 dynamics in ovarian cancer. *Cell* 2018, **173**:1755-1769. e1722.
- 857 61. Levine JH, Simonds EF, Bendall SC, Davis KL, El-ad DA, Tadmor MD, Litvin O,
 858 Fienberg HG, Jager A, Zunder ER: Data-driven phenotypic dissection of AML
 859 reveals progenitor-like cells that correlate with prognosis. *Cell* 2015, 162:184-197.
- 860 62. Xu C, Su Z: Identification of cell types from single-cell transcriptomes using a
 861 novel clustering method. *Bioinformatics* 2015, 31:1974-1980.
- 862 63. Hegde PS, Chen DS: Top 10 challenges in cancer immunotherapy. *Immunity* 2020,
 863 52:17-35.
- Motzer RJ, Banchereau R, Hamidi H, Powles T, McDermott D, Atkins MB, Escudier B,
 Liu L-F, Leng N, Abbas AR: Molecular subsets in renal cancer determine outcome
 to checkpoint and angiogenesis blockade. Cancer Cell 2020, 38:803-817. e804.
- 867 65. O'Donnell JS, Teng MW, Smyth MJ: Cancer immunoediting and resistance to T cell 868 based immunotherapy. Nature reviews Clinical oncology 2019, 16:151-167.
- 869
- 870
- 871

872 Acknowledgements

873 Funding

- 874 We thank members of the Chan lab for their suggestions and critical reading of the manuscript.
- We acknowledge funding sources including NIH R01 CA205426 (T.A.C.), NIH R35 CA232097
- 876 (T.A.C.), DOD grant KC180165, NIH R01 DE027738 (to L.G.T.M.), the NIH/NCI Cancer Center
- 877 Support Grant P30 CA008748 (to MSKCC), P30 core grants (to MSKCC), Ludwig institute
- 878 (A.A.H.), Weiss family fund (A.A.H.), Department of Defense (A.A.H.) and Illumina Inc.

879

880 **Contributions**

- 881 M.G. performed data analysis and wrote the manuscript with input from all authors. M.G., A.A.H.,
- 882 T.A.C., and E.R. conceived the study and contributed to data interpretation. F.K., E.R., C.T., V.M.,
- 883 S.Z., C.Z., and R.M. assisted with analytical methodology development and bioinformatics
- support. M.L.S., R.V., L.L., T.P., and J.G. contributed to DNA, RNA, and TCR sequencing. R.J.M.,
- 885 M.I.C., P.R., J.C., L.G.T.M., and M.H.V. cared for patients analyzed in the study. K.A.B. and
- 886 R.G.N. handled patient samples. R.G.N. collected and analyzed clinical metadata. S.G. and Y.C.
- analyzed H&E images. All authors read and approved the manuscript.

888

889 Ethics declarations

890 Ethics approval and consent to participate

- 891 Informed consent and institutional review board approval were acquired at Memorial Sloan892 Kettering Cancer Center (MSK).
- 893 **Consent for publication**
- Not applicable.

895 Competing interests: M.G., R.V., M.L.S., J.G., T.P., R.M., C.Z., S.Z., L.L., are current employees 896 and shareholders of Illumina Inc. T.A.C. and L.G.T.M. are inventors on a patent held by Memorial 897 Sloan Kettering related to the use of TMB in cancer immunotherapy. MSK has licensed the use 898 of TMB for the identification of patients that benefit from immune checkpoint therapy to PGDx. 899 L.G.T.M. reports laboratory research funding from AstraZeneca. T.A.C. is a co-founder of 900 Gritstone Oncology and holds equity. T.A.C. holds equity in An2H. T.A.C. acknowledges grant 901 funding from Bristol-Myers Squibb, AstraZeneca, Illumina, Pfizer, An2H, and Eisai. T.A.C. has 902 served as an advisor for Bristol-Mvers Squibb. Illumina. Eisai, and An2H. R.J.M. reports 903 consulting fees from Aveo, Calithera, Eisai, Eli Lilly, EMD Serono, Genentech, Merck, Novartis 904 AG, Pfizer, and Roche, and contracted research to employer MSKCC for Bristol Myers Squibb, 905 Eisai, Exelixis, Genentech, Merck, Pfizer, and Roche. A.A.H. is on the advisory board for Merck. 906 M.H. receives commercial research grants from Bristol-Myers Squibb, Pfizer and 907 Genentech/Roche, honoraria from Novartis, Bristol-Myers Squibb, travel/accommodation from 908 Astra Zeneca, Eisai, Novartis and Takeda, and is a consultant/advisory board member for Alexion 909 Pharmaceuticals, Aveo, Calithera Biosciences, Corvus Pharmaceuticals, Exelixis, Eisai, 910 GlaxoSmithKline, Merck, Natera; Onguality Pharmaceuticals; Novartis and Pfizer. Other authors 911 declare no competing interests.

912

913 Figures and Tables

Figure 1. Patient characteristics and study design. a) Multi-regional multi-omics was performed on 29 patients. b) In total, 6 out of 29 patients were untreated and the rest were treated with ICI or in combination with TKI. TCRseq of PBMC was performed at 4 time points on therapy for a subset of patients. In addition, pathological review was performed to assign N-TIL (tumors sparsely infiltrated by TILs), S-TIL (tumors dominated by stromal TILs), and ES-TIL (tumors with

substantial levels of both epithelial and stromal TILs) classes to a subset of patients. c)
Additionally, scRNAseq data for 6 patients were available from [15].

921

922 Figure 2. TME ITH in ccRCC. a) Intra-tumoral heterogeneity of several gene expression 923 signatures across multiple tumor regions. Radar charts show Z-score of each feature normalized 924 across the cohort. Min and max radius for each feature in each panel represent min and max of 925 that feature across the cohort. b) For each gene signature, the number of patients who were 926 classified as high or low or a mixture of high and low across tumor regions are shown. Two 927 patients (MR05 and NIVO10) were excluded since WTS data of only one region was available. 928 Also, pre-treatment regions of ICI treated patients were excluded to avoid treatment-related 929 effects in these signatures. c) Intra-tumoral heterogeneity of myeloid score observed across 930 multiple regions of tumors of patients in this study.

931

932 Figure 3. Landscape of ITH in ccRCC. a) Oncoprint of key ccRCC driver mutations and copy 933 number alterations for all regions of all 29 patients in this cohort. Margin shows comparison 934 between mutation frequency observed in this cohort and TRACERx Renal. b) We have performed 935 unsupervised hierarchical clustering of genomic features including patient level presence or 936 absence of a small variant in VHL, PBRM1, SETD2, BAP1 (most commonly mutated genes) as 937 well as loss of heterozygosity in HLA genes as well as 9p (which includes CDKN2A/B) SCNA 938 which are known to affect ICI response. Heatmap shows ITH high vs low classification across 939 data type. Annotation illustrates evolutionary subtypes and treatment status of patients. A patient 940 is annotated as wildtype if all regions are wild type for that alteration. Cases where ITH score 941 could not be calculated due to lack of sufficient number of biopsies are shown in gray pixels. CIN: 942 chromosome instability. c) Association between antigen presentation machinery (APM), effector 943 T cell (Teff) and myeloid gene signatures and ITH. Wilcox P, False Discovery Rate (FDR) and

Linear Mixed Effect (LME) P shown. **d)** Intra-tumoral heterogeneity and myeloid score are associated with CDKN2A/B loss in TCGA KIRC cohort. **e)** ITH low patients show a significantly higher TCR diversity, richness and clone count.

947

948 Figure 4. The landscape of heterogeneity of neoantigen depletion. a) Change in the number 949 of non-synonymous binder SNVs (predicted in silico) and non-synonymous non-binder SNVs 950 compared to pre-treatment. Reduction in only putative neoantigens illustrates selective pressure 951 and immunoediting. One sample Wilcox test P (compared to zero) is shown. b) Clonality of 952 neoantigen depletion. Only strong binders are shown. c, d) Immunoediting in an HLA-intact 953 patient NIVO20 through reduced neoantigen expression. NKA/NKB/NKC (shown in RED) are 954 normal adjacent tissues 1cm, 2cm, and 4cm away from the center of the tumor; BX (shown in 955 blue) represents pre-treatment biopsy; RA/RB/RC/RD/RE (shown in green) illustrate 5 tumor 956 regions from the treated tumor sample. e) Immunoediting with amino acid resolution. Higher 957 Phenylalanine (F) depletion compared to Glutamic Acid (E) and Arginine (R) suggests immune 958 selection. f) Association between putative neoantigen depletion and myeloid activation across all 959 regions of patients where pre-treatment WES data was available (n = 16 patients). **q)** Association 960 between the fraction of expressed putative neoantigens depleted and immune signatures. In (g) 961 correlations are calculated across different regions of the same patient, for all patients with >3 962 treated as well as pre-treatment RNA samples were available (n = 7 patients). h. i) HERVs are 963 enriched in tumors compared to normal samples and are associated with treatment. j) HERV 964 depletion association with myeloid signature. k) Circos plot (left) illustrates the fraction of shared 965 T cell clonotypes between tissue and different time points on therapy. Ribbons connecting 966 different regions of the tumor are scaled based on clonotype overlap. (right) clonotype tracking of 967 dominant untreated T cell clones in treated regions of patient NIVO20. The color of each ribbon 968 shows different T cell clones, and the width is scaled corresponding to the frequency of that clone.

Tissue data consists of 5 tumor regions after treatment (RA/RB/RC/RD/RE), one single normal adjacent (NKC), and one tumor region pre-treatment (BX). Likewise, PBMC data points on treatment are NIVO20-68, -54, -40, -12. **I**, **m**) TCR diversity is negatively associated with neoantigen depletion and HLA LOH.

973

Figure 5. Branch evolution demonstrates immune evasion. a) Evolutionary tree illustrates tumors can exploit concurrent HLA LOH and CDKN2A/B loss to escape immune surveillance. b) Co-occurrence of HLA LOH and CDKN2A/B can be seen both across regions and patients. c) Differential immune response to ICI therapy in patients with CDKN2A/B loss or HLA LOH or belonging to ITH high subtype. d) Regions of tumor associated with immune escape depict a distinct pathology where colocalization of TILs and stroma can be observed.

980

981 Figure 6. Immunoediting correlates with stroma and myeloid signatures. a) WGCNA 982 identifies gene expression modules associated with inflammation ("JAVELIN-like"), angiogenesis, 983 and Immune Escape. Gene dendrogram was first generated and then modules were extracted 984 using dynamic tree cutting (top). Modules were annotated by comparing the correlation between 985 the module eigengenes and previously known gene signatures describing different phenotypes 986 (bottom). b) Modules 7 (black), 4 (salmon), and 16 (magenta) are associated with previously 987 described signatures, JAVELIN, angiogenesis and myeloid/stroma. c) scRNAseg demonstrates 988 the cell type enrichment of Immune Escape signature in ccRCC patients. Different colors 989 represent different cell types inferred from scRNAseg data. UMAP plot illustrates single cells 990 collected from all 6 patients including treated and untreated patients. Computational extracted 991 clusters were annotated as previously described [15] d, e) Association between ITH groups, 992 Immune Escape signature and N/S/ES pathologies. f) These regions demonstrate an elevated

Immune Escape gene signature in NIVO21. RA, RB, RC, RD, and RE denote different regions ofa tumor sample.

995

996 Figure 7. Association between immune escape and clinical outcome to checkpoint 997 blockade. Survival analysis shows the association between gene signatures obtained in this 998 study and clinical outcome of different independent retrospective trials. a) Immune Escape and 999 JAVELIN-like signatures are associated with PFS in patients treated Avelumab plus Axitinib in 1000 JAVELIN Renal 101 cohort. b) Immune Escape signature, but not the JAVELIN-like signature, 1001 correlates with the response to Atezolizumab plus Bevacizumab in IMmotion151 but not JAVELIN 1002 signature. c) Immune Escape signature, but not the JAVELIN-like signature, correlates with the 1003 efficacy of anti-PD1-treament in CheckMate 009, 010, 025.

1004

Figure 8. A hypothetical model for spatiotemporal evolution of ccRCC links ITH to immune escape and adverse TME. Cancer cell death, potentially by cytotoxic killing, early in tumor evolution selects for tumor clones with HLA LOH and/or CDKN2A/B loss. This promotes the evolution of a TME depleted of antigen-specific T cells and enriched for myeloid cells.

1009

1010 Supplementary Figure Legends

Fig. S1. Validation of TME associated gene signatures using IF. Myeloid signature correlates
 with CD11b/CD68 markers. CD31 endothelial and CD8 T cell markers are correlated with
 Angiogenesis and JAVELIN signatures.

1014 Fig. S2. ccRCC evolutionary subtypes and their association with angiogenic TME score.

Fig. S3. Clonotype overlap analysis. a) Hierarchical clustering of TCR clonotypes across
 different regions of patients where tissue TCRseq data was available. B) Rarefration analysis of

1017 ITH high vs ITH low patients **c)** Circos plot illustrates the fraction of shared T cell clonotypes 1018 between tissue and different time points on therapy. Ribbons connecting different regions of the 1019 tumor are scaled based on clonotype overlap. Labels show patient ID followed by time to 1020 nephrectomy (e.g., NIVO09-7: patient NIVO09 at 7 days to nephrectomy) **d)** Number of CDR3 1021 clone counts shown for all samples where TCR seq was performed.

Fig. S4. Boxplots show total and change compared to pre-treatment (when sample was available) for mutational count, and neoantigen count across different regions of all patients. Count change is shown only for 16 patients whose pre-treatment WES data was available.

Fig. S5. Association between neoantigen loss and myeloid signature. a) No association between TMB and tumor purity (FACETS) was observed b) Association between total number of neoantigens depleted and myeloid signature. c) The fraction of mutations or neoantigens depleted is not correlated with tumor purity for samples with tumor purity larger than 0.3; however, the association between myeloid signature and neoantigen depletion remains strong even after excluding samples with low purity. d) Association between immune elimination and escape with myeloid signature.

1033 Fig. S6. Comparison between SNPs neoantigen depletion and INDEL depletion.

Fig. S7. Treatment impact of HERV association with TME. a) Association between HERV
 expression and immune signatures. b) PBRM1 mutations are associated with elevated HERV
 expression. c) Association between ClearCode34 classes and HERV expression. d) Association
 between ClearCode34 classes and neoantigen depletion.

1038 Fig. S8. Association between immune escape signature and treatment.

1039 Fig. S9. Validation of escape signature in independent cohorts (IMmotion151). a) Escape

- 1040 signature is associated with improved survival in patients treated with ICI but not sunitinib. b)
- 1041 Escape signature is associated with CDKN2A/B alteration in Immotion151.

1042 Fig. S10. Relationship between escape gene signature and treatment outcome in different

- 1043 **clinical trials.** HRs are calculated for each threshold for ICI or ICI in combination with TKI arms
- 1044 in JAVELIN Renal 101, IMmotion151, and CheckMate 009, 010, 025.
- 1045 **Fig. S11. Refinement of immune escape gene signature. a)** 85 genes immune escape gene
- signature is strongly associated with response to Avelumab plus Axitinib in JAVELIN Renal 101
- 1047 trial. b) Pairwise spearman correlation between 85 genes in module 16 (immune escape). c)
- 1048 Refinement of 85 genes into 12 genes with the highest pairwise spearman correlation.
- 1049
- 1050
- **Supplementary Materials**
- 1052
- 1053 Supplementary Tables
- 1054 **Table S1:** Data availability.
- 1055 **Table S2:** Patient characteristics and relevant clinical data.
- 1056 **Table S3:** WTS related gene signatures.
- 1057 **Table S4:** ITH classification.















m

Spearman correlation = -0.53

• •

0.6

fraction of neoantigens depleted

0.8

1.0

P = 0.001

0.4

0.2

CDKN

1.0

120

entropy)

ICR diversity (Shannon



figure margins too large

ccA c1 N CDKN2A/B^{wt} HLA^{wt}

ccA c1 N CDKN2A/Bloss HLA wt

ccA c1 N CDKN2A/Bloss HLA wt

CDKN2A/Bloss HLALOH

CDKN2A/Bloss HLALOH

neo.editing

ccB c4

ccB c4

RD RE

NIVO12: ITH

d





Ν

S

ES



а





Endpoint Subgroup HR CI р module #16: PFS_P 1.09 (0.86-1.38) 0.467 Immune Escape: high module #4: 0.48 (0.38-0.61) < 0.001 angiogenesis-like: high module #7: 1.05 (0.83-1.32) 0.690 JAVELIN-like: high

DA Braun et al. (CheckMate 009, 010, 025) n=130

С

DA Braun et al. (CheckMate 009, 010, 025) n=181

Anti-PD1-treatment



mTOR inhibition













BAP1 driven
multiple clonal driver
PBRM1->PI3K
PBRM1->SCNA
PBRM1->SETD2
VHL monodriver

VHL wildtype



only samples with tumor purity (FACETS) > 0.3 included









Association between immune signatures and median HERV expression (not corrected for purity)



Association between immune signatures and median HERV expression (corrected for purity)



а







threshold (quantile)

